NewsRoom Articles - Page 29 of 44

TuesdayDec 13, 2022 10:30 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) 2022 Calendar Year in Review

Lexaria Bioscience is a global innovator in drug delivery platforms whose patented DehydraTECH(TM) technology has demonstrated the ability to improve the bioavailability and increase the speed of onset of many drugsIn calendar 2022, the company achieved a number of milestones in various areas, including research programs, receipt of patents, and licensing agreementsLexaria started and completed its fourth and most comprehensive hypertension study yet, investigating the capabilities of DehydraTECH-CBD, with the study showing that its formulation resulted in a sustained reduction in blood pressure over the study period (five weeks)The company has also started investigating DehydraTECH-CBD as a potential therapeutic for…

MondayDec 12, 2022 10:30 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Has Potential to Make History in Battle Against Deadly Brain Cancer with Berubicin

Glioblastoma, also known as GBM, is a fatal and incurable brain cancer that tends to recur aggressively after initial treatmentCNS Pharmaceuticals is a U.S.-based pharmaceutical innovator whose flagship drug candidate, Berubicin, is a potentially pivotal treatment for treating GBM because of its novel apparent ability to cross the blood-brain barrier at effective levelsCNS is building upon prior clinical trial outcomes with its global potentially pivotal trial currently registering patients in the United States and EuropeBerubicin’s development is being advanced with potential time and cost savings thanks to the FDA’s decision to grant it Fast Track and Orphan Drug status The…

MondayDec 12, 2022 9:45 am

Vision Energy Corp. (VENG) Announces Ticker Change and Engages Rho Adviseurs for Planning Services in the Development of Europe’s First Green and Low-Carbon Energy Terminal

Rho Adviseurs has been engaged by Vision Energy, a growing renewable energy facilities developer, to provide specialist studies for environmental impact assessment and policy, process guidance, and spatial planning, all required for the permit applications for Vision’s Green Energy HubVision Energy’s Green Energy Hub is positioned to be the first terminal in Europe focused on green and low-carbon energy products, and located in the North Sea Port of Vlissingen at the mouth of the Westerschelde estuaryVision Energy is focused on governments that support regulatory standards promoting hydrogen production and alternatives to traditional fossil fuels in support of green energy solutions…

SundayDec 11, 2022 9:00 am

Cepton, Inc. (NASDAQ: CPTN) Announces Collaboration with Exwayz, as Lidar is Quickly Becoming an Essential Sensor Technology Within the Robotics Sector

Autonomous robotics are increasingly being used to automate manual logistics processesIn addition to its own software solutions, Cepton collaborates with software provider Exwayz to present a robotic solution for global customersThe company recently announced that it will unveil its upcoming next-generation automotive lidar solution, the Vista-X120 Plus, at the forthcoming CES 2023 event in Las VegasAs part of that product launch, Cepton has been recently recognized as a 2023 Innovation Award honoree by CES within the vehicle tech and advanced mobility category In early June, Amazon unveiled its new fleet of autonomous robots, designed to revolutionize the way that half…

WednesdayDec 07, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Findings of Animal Anti-Seizure Study Program Suggesting that DehydraTECH(TM)-CBD Is More Effective at Lower Doses and Works More Rapidly than FDA-Approved Epidiolex

Lexaria recently announced the findings of the first two studies from its EPIL-A21-1 animal research programThe program is designed to assess the effectiveness of patented DehydraTECH(TM)-CBD in reducing or eliminating seizure activity compared to Epidiolex, a CBD-based anti-seizure drugThe first study evidenced that DehydraTECH-CBD is more efficacious at lower doses than EpidiolexThe second study demonstrated DehydraTECH-CBD’s enhanced effectiveness; specifically, the formulation acted more rapidly than Epidiolex Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) formulation has demonstrated performance enhancements compared to Epidiolex(R), the first and only FDA-approved CBD medication for…

FridayDec 02, 2022 9:45 am

Vision Energy Corp. (VIHDD) Develops Carbon-Reduced Solutions for Commercial, Industrial, and Transportation Industries, as It Pursues Landmark Design for First European Terminal

The European Green Deal, with the objective to become climate-neutral by 2050, implies a near-total phase-out of fossil fuels in the EU energy systemVision Energy signed a cooperation agreement with Linde Engineering to accelerate efforts for its pioneering Green Energy Terminal in the North Sea Port of Vlissingen, the NetherlandsEngineering efforts under the agreement have commenced and are anticipated to conclude in April 2023, supporting the company’s target to reach a Final Investment Decision by Q3 2023 Hydrogen presents a global opportunity to reduce greenhouse gas emissions due to its high efficiency and zero-or near-zero-emissions operation. The global hydrogen market…

FridayDec 02, 2022 9:00 am

Cepton, Inc. (NASDAQ: CPTN) Launches ‘Periscope’ Lidar-Based Sensory System Designed to Increase Pedestrian Safety

70% of total fatalities in urban areas are vulnerable road usersAs of 2000, a U.S.-based pedestrian was involved in a fatal accident every 81 minutesIn conjunction with its technological partners, Cepton has designed a lidar-based road sensor, directed to warn drivers about potential pedestrian activity around a corner 5 seconds before they would otherwise be visibleDespite its original intended use as an advanced motion-system tool, the use of lidar technology has far surpassed its original necessitiesToday, lidar technology is being used within a wide array of initiatives and industries, ranging from security and safety solutions, smart railways, and traffic control…

WednesdayNov 30, 2022 9:00 am

Cepton, Inc. (NASDAQ: CPTN) Launches ‘Periscope’ Lidar-Based Sensory System Designed to Increase Pedestrian Safety

70% of total fatalities in urban areas are vulnerable road users As of 2000, a U.S.-based pedestrian was involved in a fatal accident every 81 minutes In conjunction with its technological partners, Cepton has designed a lidar-based road sensor, directed to warn drivers about potential pedestrian activity around a corner 5 seconds before they would otherwise be visible Despite its original intended use as an advanced motion-system tool, the use of lidar technology has far surpassed its original necessities Today, lidar technology is being used within a wide array of initiatives and industries, ranging from security and safety solutions, smart…

TuesdayNov 29, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Investigation of DehydraTECH-CBD’s Potential Therapeutic Value for Diabetes and Defmentia with New Studies

Lexaria’s Patented DehydraTECH technology improves the bioavailability of pharmaceuticals and therapeutics for a number of developing applications Lexaria is set to complete its DEM-A22-1 and DIAB-A22-1 studies on dementia and diabetes, respectively, in January 2023, with analysis and reporting set to follow soon after These studies will build on the just-concluded hypertension clinical study whose results were “truly exceptional,” demonstrating a statistically significant lowering of blood pressure in the patient population over multiple weeks There is an established link between hypertension and vascular dementia, along with hypertension being twice as frequent in people with diabetes and hypertensive patients being at…

MondayNov 28, 2022 9:00 am

European Clinical Trial Site Expansion for CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Brain Cancer Drug Candidate Drives Patient Enrollment

U.S.-based drug innovator CNS Pharmaceuticals is continuing to advance its global human clinical trial for Berubicin, a potentially pivotal treatment for the incurable brain cancer glioblastomaCNS recently announced its Q3 financial results, including an update on the clinical development that noted the start of patient enrollment and dosing in FranceCNS is also advancing trial sites in the United States, Switzerland, Spain, and Italy, with 29 of 68 anticipated sites currently enrolling patientsThe company expects to provide an interim analysis of the trials in mid-2023 and primary completion in 2024, with ultimate resolution in 2025 The FDA has granted Berubicin Fast Track…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) 2022 Calendar Year in Review

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Has Potential to Make History in Battle Against Deadly Brain Cancer with Berubicin

Vision Energy Corp. (VENG) Announces Ticker Change and Engages Rho Adviseurs for Planning Services in the Development of Europe’s First Green and Low-Carbon Energy Terminal

Cepton, Inc. (NASDAQ: CPTN) Announces Collaboration with Exwayz, as Lidar is Quickly Becoming an Essential Sensor Technology Within the Robotics Sector

Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Findings of Animal Anti-Seizure Study Program Suggesting that DehydraTECH(TM)-CBD Is More Effective at Lower Doses and Works More Rapidly than FDA-Approved Epidiolex

Vision Energy Corp. (VIHDD) Develops Carbon-Reduced Solutions for Commercial, Industrial, and Transportation Industries, as It Pursues Landmark Design for First European Terminal

Cepton, Inc. (NASDAQ: CPTN) Launches ‘Periscope’ Lidar-Based Sensory System Designed to Increase Pedestrian Safety

Cepton, Inc. (NASDAQ: CPTN) Launches ‘Periscope’ Lidar-Based Sensory System Designed to Increase Pedestrian Safety

Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Investigation of DehydraTECH-CBD’s Potential Therapeutic Value for Diabetes and Defmentia with New Studies

European Clinical Trial Site Expansion for CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Brain Cancer Drug Candidate Drives Patient Enrollment

TinyGems

Quote / Research

Site Search